[Diagnosis and treatment of urinary bladder dysfunctions in patients with nephrotuberculosis].
A combined, including urodynamic, study was made in 129 patients with abnormal reservoir function of the urinary bladder (UB). Of them, 82 patients had nephrotuberculosis (NT). Cystoscopy was made in 93 patients, endovesical multifocal biopsy of the bladder wall-- in 23. Correction was conducted with alpha-adrenoblocker alfusozine. In NT, sensory functional disorders of UB prevail (60%). The degree of fibrous-inflammatory involvement of the bladder wall by biopsy findings and severity of urodynamic disorders do not correlate (r < 0.03). Miction recovered in 81.5% patients with NT taking alfusozine. Ileocystoplasty (n = 20) was made in treatment failure and total UB fibrosis. Long-term pathogenic action of specific infection on the neuroreceptor system of the UB may cause defects in its activity. Complex urodynamic investigations of the lower urinary tracts in NT patients identify the type of the disorder and help in making choice of pharmacological or surgical correction. Alfusoxine is a drug of choice in UB hypersensitivity.
Zuban'
O N
ON
Iagafarova
R K
RK
Vinogradova
T I
TI
D000293:Adolescent; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008333:Mandelic Acids / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D010276:Parasympatholytics / Q000008:administration & dosage / Q000627:therapeutic use; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D014398:Tuberculosis, Renal / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D001743:Urinary Bladder / Q000187:drug effects / Q000294:innervation / Q000473:pathology; D001745:Urinary Bladder Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D014563:Urodynamics / Q000187:drug effects*
D000317:Adrenergic alpha-Antagonists; D000995:Antitubercular Agents; D008333:Mandelic Acids; D010276:Parasympatholytics; D011799:Quinazolines; C047638:alfuzosin; C005419:oxybutynin